Paying too sits at the center of this dementia and brain health question.
Millions of Americans with diabetes are paying far more than they should for insulin because the federal $35 monthly cap only covers Medicare beneficiaries, leaving privately insured and uninsured patients exposed to prices that remain seven to ten times higher than what people pay in other developed countries. An uninsured diabetic filling a prescription today still faces an average out-of-pocket cost of $123 per fill, more than double the overall average, and 21 states have passed no copay caps whatsoever for commercial insurance plans. For the estimated 8.4 million Americans who depend on insulin to survive, the patchwork of manufacturer discounts, state laws, and federal protections means that where you live, how you are insured, and which pharmacy benefit manager controls your plan can determine whether you pay $35 or $300.
This matters for readers of a brain health site because diabetes and dementia are deeply connected. Poorly managed blood sugar accelerates cognitive decline, and people who skip or ration insulin due to cost are putting their brains at serious risk. This article breaks down exactly who is covered by existing price caps, why pharmacy benefit managers inflated costs for years, what manufacturer price cuts actually mean in practice, and what steps patients can take right now to lower their insulin bills.
Table of Contents
- Why Are So Many Diabetics Still Overpaying for Insulin in 2026?
- How Pharmacy Benefit Managers Drove Insulin Prices Through the Roof
- What the Manufacturer Price Cuts Actually Mean for Patients
- What Diabetics Can Do Right Now to Lower Their Insulin Costs
- The Diabetes-Dementia Connection and Why Insulin Access Is a Brain Health Issue
- State-Level Momentum and Where the Gaps Remain
- What Comes Next for Insulin Pricing in the United States
- Conclusion
- Frequently Asked Questions
Why Are So Many Diabetics Still Overpaying for Insulin in 2026?
The short answer is that the most significant federal price protection, the Inflation Reduction Act’s $35 monthly insulin cap, applies exclusively to Medicare Part D enrollees. There is no federal cap for the roughly 160 million Americans on private employer-sponsored insurance or for the tens of millions who are uninsured. While 29 states plus Washington, D.C., have enacted their own insulin copay caps for state-regulated commercial plans, these laws vary widely in scope. California’s $35 cap for large group insurers only took effect in 2026, with individual and small group plans not covered until 2027. If you live in one of the 21 states without any commercial copay cap, your insurer can still pass along hundreds of dollars per month.
The scale of the problem is staggering. The CDC reports that 40.1 million Americans have diagnosed or undiagnosed diabetes, roughly 12 percent of the entire population. Over 2 million have Type 1 diabetes and require insulin to stay alive. Approximately 15 percent of the much larger Type 2 population also depends on insulin. When insulin costs force people to ration doses, the consequences go far beyond blood sugar. Chronic hyperglycemia damages blood vessels throughout the body, including those that feed the brain, raising the risk of vascular dementia and accelerating Alzheimer’s disease progression.
How Pharmacy Benefit Managers Drove Insulin Prices Through the Roof
For years, three pharmacy benefit managers, CVS Caremark, Express Scripts, and OptumRx, have controlled an estimated 80 percent of the insulin market. The Federal Trade Commission alleged in a September 2024 lawsuit that these PBMs systematically chose higher-priced insulin products because those products came with larger rebates that the PBMs pocketed, while patients were stuck paying inflated list prices at the pharmacy counter. In other words, the middlemen had a financial incentive to keep prices high. The FTC’s case has already produced results. On February 4, 2026, the agency secured a landmark settlement with Express Scripts requiring transparency reforms projected to save patients up to $7 billion over the next decade.
State and local governments are piling on as well. Delaware filed suit against PBMs and manufacturers in January 2026, and Philadelphia did the same in December 2025, both alleging coordinated price-gouging stretching back 15 years. However, if your employer’s insurance plan is self-funded, which many large companies use, state copay cap laws generally do not apply because self-funded plans are regulated under federal ERISA rules, not state insurance law. This is a critical gap that leaves millions of privately insured workers without the protections their state legislature may have passed. You can have a state with a $35 insulin cap on the books and still pay full price if your employer self-insures.
What the Manufacturer Price Cuts Actually Mean for Patients
The three major insulin manufacturers have all announced significant price reductions. Eli Lilly cut its insulin list prices by 70 percent and caps patient out-of-pocket costs at $35 per month through its Lilly Insulin Value Program. Novo Nordisk lowered U.S. list prices for Tresiba and Fiasp by more than 70 percent starting January 1, 2026. Sanofi expanded its $35 monthly insulin cap to all U.S. patients, including uninsured individuals, as of January 2026. Meanwhile, Civica, a nonprofit generic drug maker, launched affordable insulin pens on January 1, 2026, with a consumer price capped at $55 per box compared to $150 to $500 from the major brands. These cuts are real and meaningful for many patients.
An uninsured person who previously paid full list price for Humalog could see their costs drop dramatically under Lilly’s program, and Sanofi’s expansion to cover the uninsured fills a gap that federal policy has not addressed. Insulin Lispro is now available for as low as $25 per month through some programs. But there is a critical caveat. Every one of these manufacturer programs is voluntary. Companies can change the terms, raise the caps, or end the programs entirely at any time. They are not codified in law. A patient who builds their treatment plan around a $35 manufacturer cap could find themselves facing hundreds of dollars in costs if the company decides the program no longer makes business sense. For someone managing both diabetes and early cognitive decline, that kind of sudden disruption to medication access can be dangerous.
What Diabetics Can Do Right Now to Lower Their Insulin Costs
The first step is knowing which protections already apply to you. If you are on Medicare Part D, the $35 monthly insulin cap is automatic, and starting in 2026, your total out-of-pocket drug costs are capped at $2,100 per year. You do not need to enroll in a separate program. If you are on commercial insurance, check whether your state has an insulin copay cap by visiting the American Diabetes Association’s state-by-state tracker. If your state has a cap but your employer self-funds its plan, the cap likely does not apply, and you will need to explore manufacturer programs instead. For uninsured patients, the comparison is straightforward but requires research.
Sanofi’s program now caps costs at $35 per month for all patients regardless of insurance status. Lilly’s Insulin Value Program offers the same $35 cap. Civica’s insulin pens cost $55 per box, which is higher than the manufacturer programs but does not require enrollment or eligibility verification. The tradeoff is simplicity versus savings: the manufacturer programs save more money but can require paperwork, pharmacy coordination, and ongoing enrollment. Civica’s product is available directly without jumping through hoops. For a caregiver managing medications for someone with both diabetes and dementia, the simpler path may be worth the extra $20 per month.
The Diabetes-Dementia Connection and Why Insulin Access Is a Brain Health Issue
Researchers have established that Type 2 diabetes roughly doubles the risk of developing Alzheimer’s disease and vascular dementia. Chronic high blood sugar damages small blood vessels in the brain, promotes inflammation, and disrupts insulin signaling in neurons, which the brain needs for memory formation and synaptic function. Some researchers refer to Alzheimer’s as “Type 3 diabetes” because of how central insulin resistance appears to be in the disease process. When diabetics ration insulin because of cost, they are not just risking diabetic ketoacidosis or cardiovascular events. They are accelerating the very brain damage that leads to cognitive decline.
A 2025 letter to Congress from T1 International, signed by more than 8,000 individuals, called for a nationwide cap on insulin costs for all patients, citing cases where people skipped doses, used expired insulin, or reduced their prescribed amounts to stretch a supply. For older adults who are already at elevated risk for dementia, these cost-driven compromises in diabetes management create a compounding crisis that neither the diabetes system nor the dementia care system is set up to catch. The limitation here is important to acknowledge: even with perfect insulin access, diabetes still elevates dementia risk. Affordable insulin is necessary but not sufficient. Blood sugar management needs to be paired with cardiovascular health, physical activity, cognitive engagement, and regular screening, all of which require a coordinated care approach that many patients, particularly those managing costs, do not receive.
State-Level Momentum and Where the Gaps Remain
The patchwork nature of state protections creates a geographic lottery for insulin affordability. Among the 29 states that have passed copay caps, the specifics vary. Some cap at $25, others at $50, and the definitions of who qualifies differ.
California’s phased approach, covering large group plans in 2026 and individual and small group plans in 2027, illustrates how even progressive states take years to close gaps. Meanwhile, patients in the 21 states without any commercial copay legislation are entirely dependent on manufacturer goodwill and federal Medicare protections that may not apply to them. Delaware’s January 2026 lawsuit against insulin manufacturers and PBMs signals that some states are moving beyond copay caps toward holding the industry accountable for the pricing structure itself. If these lawsuits succeed, they could create a precedent that reshapes how insulin is priced nationally, not just how much of the price patients see at the pharmacy counter.
What Comes Next for Insulin Pricing in the United States
Federal policy is slowly moving toward broader protections. On May 12, 2025, President Trump signed an Executive Order on “Most-Favored-Nation” drug pricing intended to align U.S. drug prices with those in other developed nations, and in January 2026, he called on Congress to codify these savings into law. If Congress acts, it could establish the first federal insulin price cap that covers all Americans, not just Medicare beneficiaries.
The FTC’s ongoing enforcement against PBMs adds regulatory pressure from a different direction, targeting the middlemen rather than the manufacturers. But legislation is uncertain, and voluntary manufacturer programs remain the primary lifeline for millions of patients outside Medicare. Advocacy groups continue pushing for a universal cap. Until one passes, the answer for patients and caregivers is vigilance: know what protections exist, enroll in every program you qualify for, and do not assume that because insulin prices are falling in the headlines, they have fallen at your pharmacy counter.
Conclusion
The insulin pricing crisis in the United States is improving but far from resolved. Medicare patients now have a hard $35 monthly cap. Major manufacturers have cut list prices by 70 percent and expanded assistance programs. The FTC is cracking down on PBMs. But the fundamental problem remains: there is no federal price protection for the millions of privately insured and uninsured Americans who depend on insulin. Twenty-one states have no commercial copay caps, manufacturer programs are voluntary, and self-funded employer plans often fall outside state protections entirely.
For readers concerned about brain health, the stakes extend beyond diabetes management. Every month that a patient rations insulin due to cost is a month of uncontrolled blood sugar damaging the brain’s blood vessels and neural pathways. Affordable insulin is not just a diabetes issue. It is a dementia prevention issue. If you or someone you care for has diabetes, take time to check your state’s copay cap status, explore manufacturer assistance programs from Lilly, Novo Nordisk, and Sanofi, and consider Civica’s lower-cost alternative. The savings are available, but in this fragmented system, nobody is going to find them for you.
Frequently Asked Questions
Does the $35 insulin cap apply to everyone?
No. The federal $35 monthly cap under the Inflation Reduction Act only applies to Medicare Part D beneficiaries. Privately insured and uninsured patients are not covered by the federal cap, though 29 states plus D.C. have their own copay caps for state-regulated commercial plans.
Can I get $35 insulin if I am uninsured?
Yes, through manufacturer programs. Sanofi expanded its $35 monthly cap to all U.S. patients, including uninsured individuals, as of January 2026. Eli Lilly’s Insulin Value Program also offers $35 per month regardless of insurance status. Civica offers insulin pens at $55 per box without enrollment requirements.
Why is insulin so much more expensive in the United States?
Insulin costs seven to ten times more in the U.S. than in other developed countries. The FTC has attributed much of the inflation to pharmacy benefit managers who controlled 80 percent of the market and chose higher-priced products in exchange for larger rebates, passing inflated costs to patients.
Does diabetes really increase dementia risk?
Yes. Research consistently shows that Type 2 diabetes approximately doubles the risk of Alzheimer’s disease and vascular dementia. Chronic high blood sugar damages brain blood vessels and disrupts insulin signaling that neurons need for memory and cognitive function.
What is the cheapest insulin available right now?
Insulin Lispro is available for as low as $25 per month through some programs. Sanofi and Lilly both cap patient costs at $35 per month through their respective assistance programs. Civica’s insulin pens are priced at $55 per box.
Will there ever be a federal insulin cap for all Americans?
It is being discussed. President Trump signed an Executive Order in May 2025 on drug pricing and called on Congress to codify savings in January 2026. Advocacy groups including T1 International have gathered over 8,000 signatures calling for a nationwide cap. However, no legislation has been enacted yet for non-Medicare patients at the federal level.
You Might Also Like
- Your Statin Dose May Be Too High — Here Are the Warning Signs
- Why Some Diabetics Are Being Switched From Metformin to Something Stronger
- Millions of Americans Are Taking Statins They Don’t Need — Study Says
For more, see NIH MedlinePlus — cognitive testing.
